Science News
from research organizations

New 'Idol' Grabs The Spotlight: Enzyme That Controls 'Bad' Cholesterol Discovered

Date:
June 12, 2009
Source:
University of California - Los Angeles
Summary:
Scientists have identified a new enzyme called Idol that destroys the cell receptor for LDL cholesterol, allowing more cholesterol to circulate in the blood. In blocking Idol's activity, the researchers triggered cells to make more receptor and remove more cholesterol from the body. The findings could lead to a new drug that works in conjunction with statins, or could be taken by patients that cannot tolerate statins' side effects.
Share:
       
FULL STORY

The above figure shows the LDL receptor in green (at left) and how it degrades after coming into contact with Idol (at right).
Credit: Image courtesy of University of California - Los Angeles

UCLA scientists have discovered a new mechanism that controls cells' production of low-density lipoprotein (LDL), the so-called "bad" cholesterol that is often linked to medical problems like heart disease, stroke and clogged arteries.   

In the body, cells in the liver produce a specific receptor that sticks to LDL and removes it from the blood, lowering cholesterol levels. Statin drugs also reduce LDL cholesterol levels by boosting cells' production of the receptor.  

In research published in the June 11 online edition of the journal Science, the UCLA team used a mouse model to identify an enzyme called "Idol" that destroys the receptor, permitting more LDL cholesterol to circulate in the blood. By blocking Idol's activity, the researchers induced cells to produce more of the receptor and absorb more cholesterol from the body.  

"We only know of three pathways that regulate the LDL receptor. The first two are already targeted by existing drugs," said principal investigator Dr. Peter Tontonoz, a professor of pathology and laboratory medicine at the David Geffen School of Medicine at UCLA and a Howard Hughes Medical Institute investigator. "Idol is the first mechanism discovered in several years that may lead to a new medication designed to control cholesterol levels."

The findings suggest that development of a drug that interferes with Idol's activity could influence cholesterol metabolism and lower levels of bad cholesterol. Doctors could prescribe the new medication in conjunction with statin drugs, which also cut cholesterol levels by targeting a different enzyme linked to the LDL receptor. This could benefit patients who cannot tolerate statin-related side effects.

Tontonoz collaborated with UCLA's Noam Zelcer, Cynthia Hong and Rima Boyadjian on the research, which was funded by the Howard Hughes Medical Institute and the National Heart, Lung and Blood Institute.   

The university has filed a patent related to the research findings.  


Story Source:

The above post is reprinted from materials provided by University of California - Los Angeles. Note: Materials may be edited for content and length.


Journal Reference:

  1. Noam Zelcer, Cynthia Hong, Rima Boyadjian, and Peter Tontonoz. LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor. Science, 2009; DOI: 10.1126/science.1168974

Cite This Page:

University of California - Los Angeles. "New 'Idol' Grabs The Spotlight: Enzyme That Controls 'Bad' Cholesterol Discovered." ScienceDaily. ScienceDaily, 12 June 2009. <www.sciencedaily.com/releases/2009/06/090611142531.htm>.
University of California - Los Angeles. (2009, June 12). New 'Idol' Grabs The Spotlight: Enzyme That Controls 'Bad' Cholesterol Discovered. ScienceDaily. Retrieved July 5, 2015 from www.sciencedaily.com/releases/2009/06/090611142531.htm
University of California - Los Angeles. "New 'Idol' Grabs The Spotlight: Enzyme That Controls 'Bad' Cholesterol Discovered." ScienceDaily. www.sciencedaily.com/releases/2009/06/090611142531.htm (accessed July 5, 2015).

Share This Page: